Skip to main content

Pharmacogenomics (PGx)

The Genome Company

IMPORTANT NOTE: Based on recent FDA guidance regarding Pharmacogenomics test reporting, we are modifying the Pharmacogenomic (PGx) section of our myGenome report to conform accordingly. Once these modifications are in conformity with FDA guidance, this section will be made available.

As a key feature of myGenome, we screen your individual genetic makeup to assess how effectively you metabolize or potentially react to certain medications that treat a variety of conditions, such as:

Asthma, Cardiac Arrhythmias, Clotting Disorders, Congestive Heart Failure, Depression/Anxiety, Diabetes, Epilepsy, Heartburn, Hepatitis C, HIV, Hypercholesterolemia, Hypertension, Hyperuricemia (Secondary to Chemotherapy), Immunosuppression, Inflammatory Bowel Disease, Malaria, Nausea/Vomiting, Pain, Schizophrenia, Smoking Cessation, Tuberculosis

Your report can help your physician improve a current or future medication plan to potentially:

  • Reduce or avoid medication side effects
  • Reduce time and money wasted finding the most effective medication (see chart below)
  • Provide more accurate personalized prescription or dosage
PGx Percentage Chart
Source: Brian B. Spear, Margo Heath-Chiozzi, Jeffrey Huff, “Clinical Trends in Molecular Medicine,” Volume 7, Issue 5, 1 May 2001, pages 201-204.

With your report you get:

  • Genetic results informing drug sensitivities, and interpretations of how you may metabolize certain drugs
  • Future updates as the pharmacogenomic landscape evolves, through new insights and medications

Take me back to myGenome page

Take me back to Physician page